(NASDAQ: FLGT) Fulgent Genetics's forecast annual revenue growth rate of 12.43% is forecast to beat the US Diagnostics & Research industry's average forecast revenue growth rate of 8.7%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 16.06%.
Fulgent Genetics's revenue in 2026 is $320,346,000.On average, 4 Wall Street analysts forecast FLGT's revenue for 2026 to be $10,161,742,909, with the lowest FLGT revenue forecast at $9,732,325,490, and the highest FLGT revenue forecast at $10,494,030,199. On average, 4 Wall Street analysts forecast FLGT's revenue for 2027 to be $11,651,923,598, with the lowest FLGT revenue forecast at $11,177,633,194, and the highest FLGT revenue forecast at $12,013,463,529.
In 2028, FLGT is forecast to generate $12,688,546,338 in revenue, with the lowest revenue forecast at $12,104,345,523 and the highest revenue forecast at $13,154,600,561.